anti-inhibitor coagulant complex (Rx)

Brand and Other Names:Feiba NF, Feiba VH Immuno
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for reconstitution

  • 500 units
  • 1000 units
  • 2500 units

Hemophilia A & B

Prevention and control of spontaneous hemorrhage or bleeding during surgical interventions in hemophilia patients who have autoantibodies or alloantibodies to coagulation factors; also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors

Prevention and control of bleeding

  • Joint hemorrhage: 50 units/kg IV q12hr; may increase to 100 units/kg q12hr; continue until signs of clinical improvement occur; not to exceed 200 mg/kg/day
  • Mucous membrane bleed: 50 units/kg IV q6hr, may increase to 100 units/kg q6hr for 2 doses maximum; not to exceed 200 units/kg/day
  • Soft tissue hemorrhage: 100 units/kg IV q12hr; not to exceed 200 units/kg/day
  • Severe hemorrhage (eg, CNS bleed): 100 units/kg IV q6-12hr; not to exceed 200 units/kg/day unless severity of hemorrhage justifies higher doses

Perioperative management

  • Preoperative: 50-100 units/kg IV once immediately prior to surgery
  • Postoperative: 50-100 units/kg IV q6-12hr until resolution of bleeding and healing is achieved

Routine prophylaxis

  • 85 units/kg IV every other day

Dosage Forms & Strengths

powder for reconstitution

  • 500 units
  • 1000 units
  • 2500 units

Hemophilia A & B

Prevention and control of spontaneous hemorrhage or bleeding during surgical interventions in hemophilia patients who have autoantibodies or alloantibodies to coagulation factors; also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors

Prevention and control of bleeding

  • Joint hemorrhage: 50 units/kg IV q12hr; may increase to 100 units/kg q12hr; continue until signs of clinical improvement occur; not to exceed 200 mg/kg/day
  • Mucous membrane bleed: 50 units/kg IV q6hr, may increase to 100 units/kg q6hr for 2 doses maximum; not to exceed 200 units/kg/day
  • Soft tissue hemorrhage: 100 units/kg IV q12hr; not to exceed 200 units/kg/day
  • Severe hemorrhage (eg, CNS bleed): 100 units/kg IV q6-12hr; not to exceed 200 units/kg/day unless severity of hemorrhage justifies higher doses

Perioperative management

  • Preoperative: 50-100 units/kg IV once immediately prior to surgery
  • Postoperative: 50-100 units/kg IV q6-12hr until resolution of bleeding and healing is achieved

Routine prophylaxis

  • 85 units/kg IV every other day
Next:

Interactions

Interaction Checker

and anti-inhibitor coagulant complex

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (1)

            • prothrombin complex concentrate, human

              anti-inhibitor coagulant complex increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis.

            Serious - Use Alternative (2)

            • tranexamic acid injection

              anti-inhibitor coagulant complex, tranexamic acid injection. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration ma.

              tranexamic acid injection, anti-inhibitor coagulant complex. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration ma.

            • tranexamic acid oral

              tranexamic acid oral, anti-inhibitor coagulant complex. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may increase risk for thrombosis.

              anti-inhibitor coagulant complex, tranexamic acid oral. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration ma.

            Monitor Closely (0)

              Minor (0)

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Headache

                Lethargy

                Nausea

                Chest discomfort

                Chills

                Rash

                Urticaria

                Injection site pain

                Fever

                Flushing

                Hypotension

                Myocardial infarction

                Tachycardia

                Thromboembolic events

                Hypersensitivity reactions

                Previous
                Next:

                Warnings

                Black Box Warnings

                Thrombotic and thromboembolic events have been reported during post-marketing surveillance following infusion, particularly following the administration of high doses and/or in patients with thrombotic risk factors

                Contraindications

                Treatment of bleeding occurrences resulting from deficiencies in coagulation factors VIII or IX

                DIC

                Normal coagulation mechanisms present

                Cautions

                Neonates (risk of thrombosis and/or hepatitis)

                Risk of transmissible infectious disease from human plasma (rare)

                Possibility of transient hypofibrinogenemia in children

                Administer to pregnant patients only if benefits outweigh risks

                Caution in patients with hepatic impairment

                Small amounts of factor VIII in the formulation may cause an anamnestic response

                Avoid or delay use in patients receiving treatment with antifibrolytic agents

                Only use to control bleeding in patients with coagulation deficiencies

                Discontinue in case of severe hypersensitivity reactions

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: C

                Lactation: Not studied

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Provides activated blood coagulation factors II, VII, IX and X from pooled human plasma

                May shorten the activated partial thromboplastin time of plasma containing factor VIII inhibitors

                Previous
                Next:

                Administration

                IV Preparation

                Warm drug and diluent to room temp

                Reconstitute with SWI according to manufacturers directions

                Do not refrigerate, use promptly

                IV Administration

                Slow IV injection or IV infusion

                Feiba VH/Feiba NF

                • infusion rate not to exceed 2 U/kg/min
                • complete infusion within 3 hr of reconstitution
                Previous
                Next:

                Images

                BRAND FORM. UNIT PRICE PILL IMAGE
                Feiba NF intravenous
                -
                1,750-3,250 unit vial
                Feiba NF intravenous
                -
                700-1,300 unit vial
                Feiba NF intravenous
                -
                350-650 unit vial

                Copyright © 2010 First DataBank, Inc.

                Previous
                Next:

                Patient Handout

                Patient Education
                anti-inhibitor coagulant complex intravenous

                NO MONOGRAPH AVAILABLE AT THIS TIME

                USES: Consult your pharmacist.

                HOW TO USE: Consult your pharmacist.

                SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

                PRECAUTIONS: Consult your pharmacist.

                DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

                OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

                NOTES: No monograph available at this time.

                MISSED DOSE: Consult your pharmacist.

                STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

                Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

                IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

                Previous
                Next:

                Formulary

                FormularyPatient Discounts

                Adding plans allows you to compare formulary status to other drugs in the same class.

                To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                Adding plans allows you to:

                • View the formulary and any restrictions for each plan.
                • Manage and view all your plans together – even plans in different states.
                • Compare formulary status to other drugs in the same class.
                • Access your plan list on any device – mobile or desktop.

                The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                Tier Description
                1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                NC NOT COVERED – Drugs that are not covered by the plan.
                Code Definition
                PA Prior Authorization
                Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                QL Quantity Limits
                Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                ST Step Therapy
                Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                OR Other Restrictions
                Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                Additional Offers
                Email to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Email Forms to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.